Kintai Therapeutics is uniquely focused on unlocking the power of the enteric signaling network and its signals throughout the body to fight disease and restore health. The company’s Precision Enteric Medicine™ (PEM™) compounds are based on a deep understanding of the interconnected biology of the microbiome, gut immune system, and enteric nervous system. Kintai has pioneered a new frontier in gut science, resulting in a unique understanding of a wealth of new genes, metabolites, and signaling molecules, leveraging these insights to rapidly translate into a highly actionable pipeline. Through the company’s focus on human biology, experimental medicine, bioinformatics and machine learning, Kintai has created a discovery and therapeutic development approach to identify and deliver new medicines. Kintai’s multidisciplinary expertise and its technology platform has delivered a pipeline of programs across multiple therapeutic areas.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Ulcerative colitis, Obesity, Chronic kidney disease
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):